{"filings":[{"id":705358,"accession_number":"0001213900-26-061772","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-05-28T12:09:55+00:00","items":["5.02","9.01"],"status":"ready","headline":"BiomX appoints Roy Rousso as Chief Business Officer; compensation includes $11,900/month and 200,000 share equity grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roy Rousso appointed Chief Business Officer effective July 1, 2026; will also serve as COO/CBO per consulting agreement.","Monthly base fee of $11,900 (pro-rated from $17,000 for 70% engagement), plus performance bonus up to 50% of base fee.","Equity grant of 200,000 shares of common stock, vesting in three equal annual installments from July 1, 2026.","Agreement includes 12-month non-compete and non-solicitation covenants; termination without cause requires 60 days' notice.","Rousso brings over two decades of leadership experience, most recently Head of Global BD at Flexnode."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95104,"accession_number":"0001213900-26-052213","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BiomX exits phage therapy, pivots to defense/security via DFSL and Zorronet acquisitions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued all clinical trials; former BiomX Ltd. subsidiary filed for insolvency in Israel in Dec 2025.","Acquired 60% of DFSL (LADAR detection) and 100% of Zorronet (AI security platform) to enter defense markets.","New management: Michael Oster as CEO, David Rokach as CFO appointed in Q1 2026.","Established X Security & Defense subsidiary; committed over $3M for 2026 operations.","Zorronet has projects with Elbit Systems (NIS 500k) and Rafael; DFSL LADAR ~99% detection accuracy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95103,"accession_number":"0001213900-26-044722","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"BiomX subsidiary Zorronet signs framework supply agreement with Israel Railways for AI animal detection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zorronet subsidiary signed 12-month framework agreement with Israel Railways to supply AI-powered animal detection stations.","Pilot achieved 98% success rate in keeping animals off tracks; Israel Railways invested NIS 800,000 (~$266,000) in pilot.","Initial phase covers maintenance/upgrade of 15 existing stations; Israel Railways may order additional stations.","Israel Railways holds option to invest up to $1M for 20% of Zorronet (not yet exercised).","Agreement follows recent acquisition of DFSL's LADAR detection tech, expanding rail/defense portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95102,"accession_number":"0001213900-26-042811","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"BiomX accelerates option exercise, acquires 60% stake in DFSL for $750k cash, $3M note","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash $750k, $3M convertible note (convertible at $12), 923k shares, and warrants for up to 4.6M shares at $12.","Revenue bonus: 5% of annual revenues if DFSL exceeds $25M in any fiscal year from 2027; payable in stock or cash.","DFSL develops LADAR-based detection systems for counter-UAS and perimeter security; deployed in Israel, Africa, and LA Metro.","Transaction subject to Israeli regulatory approval and NYSE American stockholder approval.","Acquisition follows prior purchase of Zorronet AI platform; technologies designed to integrate detection, analysis, and response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95101,"accession_number":"0001213900-26-042595","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BiomX shareholders approve 2026 Equity Incentive Plan at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan authorizes up to 1,390,000 shares of common stock plus annual 4% increase for 10 years.","Approved with 3,395,917 votes for, 5,009 against, 8,678 abstentions.","Adjournment proposal also passed; no adjournment needed as votes were sufficient.","Record date: March 23, 2026; 6,543,516 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95100,"accession_number":"0001213900-26-042200","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"BiomX acquires ZorroNet, enters AI defense with $1.25M note and stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of ZorroNet, an Israeli AI-powered defense tech firm, for 1.3M shares and a $1.25M non-convertible note due July 2026.","Earnout payable by March 2027: greater of 125% of 2026 revenue or 8x 2026 EBITDA.","ZorroNet has contracts with IDF, Israel Railways, and Elbit Systems; platform deployed at military bases and critical infrastructure.","BiomX also holds an option to acquire DFSL, a LADAR solutions company for C-UAS and border security.","Targets $44B command-and-control and $37B video analytics markets by 2030; acquisition immediately accretive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95099,"accession_number":"0001213900-26-038095","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BiomX secures option to buy defense-tech DFSL; $5M convertible note plus equity stakes up to 19.99%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Option to purchase 100% of Mandragola's DFSL shares; exercise after Mandragola acquires 60% of DFSL.","Consideration: $100K cash, $5M convertible note, preferred stock for 9.9% of common, pre-funded and 5-year warrants at $12 exercise for up to 19.99%.","Closing subject to Israel Innovation Authority approval of DFSL ownership transfer and standard conditions.","If DFSL annual revenue reaches $25M+ from FY2027, Mandragola receives 5% revenue bonus in cash or restricted stock.","BiomX will seek shareholder approval for issuance of >19.99% of common on conversion/exercise; proxy statement to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107937,"accession_number":"0001213900-26-035605","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"BiomX receives NYSE American delisting notice for stockholders' equity deficiency; discloses going concern","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notified for failing to meet minimum stockholders' equity requirements under Sections 1003(a)(i)-(iii) (thresholds $2M-$6M).","Must submit compliance plan by April 24, 2026; must regain compliance by September 25, 2027.","Audit opinion for FY2025 includes a going concern qualification.","Common stock (PHGE) continues trading on NYSE American; delisting proceedings possible if plan is not accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107936,"accession_number":"0001213900-26-031587","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BiomX amends warrants to 1-year term at $1 exercise; outlines strategic reset","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant term shortened to expire Dec 31, 2026; exercise price reduced from $2.00 to $1.00 per share.","CEO letter cites warrant overhang reduction and plans to reposition toward defense-related technologies.","Company finalizing closure of Maryland facility to cut overhead and strengthen financial foundation.","Active engagement with investment banks and institutional investors for future capital access.","No change in number of shares issuable upon exercise; cashless exercise VWAP formula revised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107935,"accession_number":"0001213900-26-026174","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BiomX stockholders approve share issuance above 19.99% threshold for financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At special meeting on March 11, 2026, stockholders approved issuance of common shares exceeding 19.99% of outstanding for conversion of Series Y preferred and warrants.","Proposal 1 received 528,511 votes for, 23,714 against, and 4,753 abstentions.","Proposal 2 (adjournment) received 524,578 for, 31,778 against, and 622 abstentions; adjournment not needed.","Record date was Feb 3, 2026; 1,593,516 shares of common stock outstanding and entitled to vote.","Approval relates to a securities purchase agreement dated Dec 26, 2025 and engagement with H.C. Wainwright & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107934,"accession_number":"0001213900-26-024344","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BiomX CEO and Chairman resign; Michael Oster appointed new CEO, Amir Shalom joins board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Solomon resigned as CEO and director effective March 4, 2026; no disagreement with company.","Dr. Russell Greig resigned as Chairman and director effective same date; no disagreement cited.","Board appointed Michael Oster as CEO; previously CEO of Saffron Tech Ltd. and Sattivus Tech Corp.","Board appointed Amir Shalom as Class I director; operations manager at Barzilai Medical Center.","New committee assignments: Liat Bidas chairs Audit; Amir Shalom chairs Compensation; Liat Bidas chairs Nominating and Governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107933,"accession_number":"0001213900-26-022301","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"BiomX CFO Wolfson, CDO Bassan and three directors resign; Rokach named CFO; meeting adjourned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Marina Wolfson and CDO Merav Bassan resigned Feb 24, 2026; no disagreement with company.","Directors Greg Merril, Edward Williams, and Susan Blum resigned Feb 25, 2026; no disagreement.","David Rokach appointed CFO effective Feb 27, 2026; former CEO of Newcom Finance and Granit Investment.","Special Meeting Feb 25 adjourned for lack of quorum; reconvened March 11, 2026 at 8:00 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107932,"accession_number":"0001213900-26-020374","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BiomX: Alan Moses resigns from board; Guy Arieli and Shaked Ran appointed as directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Moses resigned from BiomX board on Feb 19, 2026 for personal reasons; no disagreements with company.","Board appointed Guy Arieli as Class I director on Feb 25, term expiring at 2027 annual meeting.","Board appointed Shaked Ran as Class III director on Feb 25, term expiring at 2026 annual meeting.","Both Arieli and Ran are independent under NYSE American rules; will receive standard prorated director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107931,"accession_number":"0001213900-26-016402","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two BiomX directors resign; Liat Bidas appointed to fill vacancy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Leff and Jesse Goodman resigned from Board effective Feb 9 and Feb 11, 2026, for personal reasons; no disagreement with company.","Liat Bidas appointed as Class II Director on Feb 13, 2026, filling one vacancy; term expires at 2028 annual meeting.","Bidas is Managing Partner at UpStream Capital Group (since 2014) and a director of BioView (TASE); Board determined independence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107930,"accession_number":"0001213900-26-014298","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.01","5.02","9.01"],"status":"ready","headline":"BiomX deconsolidates Israel subsidiary after insolvency proceedings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BiomX Ltd. (wholly owned subsidiary) filed for insolvency in Israel on Jan 25, 2026; trustee appointed.","CEO Jonathan Solomon and CFO Marina Wolfson terminated as officers of BiomX Ltd. retroactive to Jan 25 (remain at parent).","Company deconsolidated BiomX Ltd. effective Feb 4, 2026, deemed a significant disposition of assets.","Pro forma shows cash of $5.4M, accumulated deficit of $205.6M; net loss for 9M 2025 reduced from $22.9M to $5.9M.","Severance payments: 9 months for CEO, 6 months for CFO and CDO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107929,"accession_number":"0001213900-26-004348","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["3.03","5.03","5.02","1.01"],"status":"ready","headline":"BiomX closes private placement, issues 3,300 Series Y Preferred shares; appoints director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 3,300 Series Y Convertible Preferred shares and warrants on January 13, 2026.","Board appointed Reuven Yeganeh as Class 1 director, effective at closing; board size increased to nine.","Yeganeh is CEO of Continual Ltd. and independent under NYSE American rules; since 2024 also director of Nukkleus Inc.","Company entered into standard indemnification agreement with Yeganeh."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107928,"accession_number":"0001213900-26-002160","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"BiomX subsidiary settles lease default with $800K payment, terminates Gaithersburg lease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seventh Amendment terminates lease for BiomX subsidiary Adaptive Phage Therapeutics effective Dec 31, 2025.","APT pays landlord $800,000 one-time cash payment; $153,557.68 letter of credit drawn by landlord.","Landlord dismisses existing repossession action with prejudice within 2 business days.","Landlord releases APT and BiomX from all further lease obligations, subject to limited survivals.","APT must remove personal property within 75 days and deliver decommissioning report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124355,"accession_number":"0001213900-25-126161","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BiomX raises $3.0M in private placement of Series Y Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $3.0M from sale of 3,300 shares Series Y Convertible Preferred (stated value $1,000/share) and warrants for 3.3M common shares.","Warrants exercisable at $2.00/share for 5 years; conversion price for preferred also initially $2.00.","Series Y Preferred carries 15% annual dividend payable quarterly in cash or common stock, maturity 1 year.","Investor gets board representation: one director if owns ≥9.99% of common; second director if ≥19.99% after stockholder approval.","Stockholders' meeting required within 60 days to approve issuance of shares exceeding 19.99% of outstanding common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124354,"accession_number":"0001213900-25-120668","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BiomX subsidiary BiomX Ltd files for insolvency; Phase 2b study discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b study discontinued Dec 8 due to resource constraints exceeding available funds.","Dec 11: Board of BiomX Ltd authorized filing for insolvency proceedings in Israel.","Company evaluating strategic options; continues BX011 program via Adaptive Phage Therapeutics.","Limited financial resources cited as primary reason for study discontinuation and insolvency filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124353,"accession_number":"0001213900-25-118969","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BiomX discontinues Phase 2b CF trial of BX004, cuts workforce, explores strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent DMC had recommended continuing Study with adjusted dosing, but company cites insufficient resources to execute alternative strategy.","Significant workforce reduction being implemented as part of cost-cutting measures.","BiomX will focus on advancing BX011 for diabetic foot infections, subject to financial resource availability.","Company is reviewing strategic alternatives to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124352,"accession_number":"0001213900-25-114833","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BiomX reports FDA clinical hold continues; DMC recommends adjusted dosing for Phase 2b CF study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA continues evaluation of third-party nebulizer used in BX004 Phase 2b cystic fibrosis study; clinical hold remains.","Independent Data Monitoring Committee recommends adjusted dosing regimen; company updating trial protocol accordingly.","Topline results now expected in Q2 2026, pending availability of financial resources and other factors.","Company working with third-party manufacturer to address FDA follow-up requests; expects to lift hold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124351,"accession_number":"0001213900-25-111265","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"BiomX approves 1:19 reverse stock split effective Nov 25, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved one-for-nineteen (1:19) reverse split on Nov 13, 2025.","Certificate of amendment filed; effective 12:01 a.m. ET on Nov 25, 2025.","New CUSIP 09090D 509; no fractional shares, rounding up to whole share.","Adjustments to equity awards, warrants, convertible preferred stock, and plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124350,"accession_number":"0001213900-25-108722","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BiomX Q3 net loss $9.2M; cash $8.1M; FDA feedback for BX011 and BX004 positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $9.2M in Q3 2025 vs net income of $9.6M in Q3 2024 due to warrant fair value changes.","Cash and restricted cash $8.1M as of Sep 30, 2025, from $18M at Dec 31, 2024; runway into Q1 2026.","R&D expenses $6.1M, G&A $2.4M; net cash used in operations $22.0M for nine months vs $30.7M in 2024.","FDA provided positive feedback on BX011 clinical pathway for S. aureus diabetic foot infections; Phase 2a planned.","BX004 clinical hold feedback imminent; Phase 2b topline results expected Q1 2026; FDA outlined potential Phase 3 pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124349,"accession_number":"0001213900-25-099755","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BiomX shareholders approve reverse stock split authorization and elect Class II directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Susan Blum, Dr. Jesse Goodman, and Gregory Merril as Class II directors until 2028.","Approved board authority to reverse split common stock at a ratio between 1-for-5 and 1-for-20 (13.6M votes for, 383.7K against).","Ratified Kesselman & Kesselman (PwC member) as independent auditor for fiscal 2025 with 14.05M votes for.","Adjournment proposal not called due to sufficient votes on other proposals.","All three proposals passed; broker non-votes were zero on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124348,"accession_number":"0001213900-25-099752","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BiomX: FDA clinical hold update – narrow nebulizer queries, no drug concerns; EU enrollment ahead","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA provided additional narrow questions on third-party nebulizer; no concerns about BX004 drug product.","BiomX believes it has fully addressed the FDA's queries.","European portion of Phase 2b study continues enrollment ahead of plan; topline results on track for Q1 2026.","FDA recognized unmet medical need for chronic Pseudomonas aeruginosa infection in CF and outlined potential Phase 3 pathways.","BiomX plans to incorporate FDA feedback into development; expects End-of-Phase 2 meeting after trial completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141023,"accession_number":"0001213900-25-078196","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA places clinical hold on BiomX's Phase 2b study of BX004 in CF due to nebulizer device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA hold pauses U.S. enrollment and screening for BX004 Phase 2b trial; no concerns about BX004 itself.","Company submitted additional data to FDA; EU study continues as nebulizer is CE marked.","Clinical hold triggered by third-party nebulizer device, not drug candidate BX004.","BiomX noted risks in ability to resume U.S. enrollment and timing of hold resolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141022,"accession_number":"0001213900-25-075272","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BiomX reports Q2 net loss $6.0M, cash $15.2M; BX211 shows >40% wound reduction in Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and restricted cash $15.2M at June 30, 2025; estimated to fund ops into Q1 2026.","Net loss $6.0M for Q2 2025 vs. income $4.5M in Q2 2024, driven by warrant fair value change.","BX211 Phase 2: >40% wound size reduction vs placebo in diabetic foot osteomyelitis; registrational study planning underway.","BX004 Phase 2b in CF successfully initiated dosing; topline results expected Q1 2026.","Nature Comm. publication: BX004 showed ~500-fold (2.7 log₁₀) bacterial reduction vs placebo with no resistance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141021,"accession_number":"0001213900-25-068990","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"BiomX sets 2025 annual meeting for Oct 16; record date Aug 22, proposal deadline Aug 15","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting scheduled for Thursday, October 16, 2025, with record date of August 22, 2025.","Stockholder proposals for proxy inclusion due by 5:00 p.m. ET on August 15, 2025, per Rule 14a-8.","Meeting date changed by more than 30 days from the 2024 annual meeting, triggering the extended notice deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141020,"accession_number":"0001213900-25-061939","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BiomX publishes Phase 1b/2a BX004 data in Nature Communications; shows 500-fold bacterial reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BX004 achieved 2.7 log10 (~500-fold) greater bacterial reduction vs placebo in CF patients with chronic P. aeruginosa infections.","No bacterial resistance to BX004 emerged during the trial, addressing a key limitation of antibiotics.","Phase 2b trial of BX004 initiated; topline results expected Q1 2026.","BX004 was safe and well-tolerated with no treatment-related safety events across all patients and dose levels.","Therapeutic phages were detected at infection site up to one week after end of therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158799,"accession_number":"0001213900-25-052377","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BiomX posts updated corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Posted updated slide deck in Investors section of website on June 9, 2025.","Presentation titled 'Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance'.","No specific financial data, guidance changes, or clinical milestones disclosed in the filing.","Filed under Regulation FD; company undertakes no obligation to update the materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158798,"accession_number":"0001213900-25-043699","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BiomX Q1 net loss $7.7M; cash $21.2M; BX004 Phase 2b topline Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.7M for Q1 2025, compared to $17.3M in Q1 2024; R&D expenses rose to $5.3M from $4.1M.","Cash and restricted cash $21.2M as of March 31, 2025; expects runway into Q1 2026.","Positive Phase 2 results for BX211 in diabetic foot osteomyelitis announced March 2025; planning Phase 2/3 trial pending FDA feedback.","BX004 Phase 2b in cystic fibrosis on track to report topline results in Q1 2026; regulatory discussions expected H2 2025.","Shareholders approved exercise of warrants from $12M February 2025 financings in April 2025, extending operational runway."],"consensus_eps_estimate":-6.9768,"consensus_eps_actual":0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158797,"accession_number":"0001213900-25-034623","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BiomX stockholders approve warrant exercise at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["16,824,049 common shares represented at special meeting on April 21, 2025.","Proposal 1 (warrant exercise approval): 16,069,898 for, 29,372 against, 18,428 abstain, 0 broker non-votes.","Proposal 2 (adjournment if needed): 16,784,878 for, 29,325 against, 9,846 abstain; not needed.","Warrants were issued in private placements and inducement letter dated February 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177204,"accession_number":"0001213900-25-025820","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BiomX Announces Positive Phase 2 Results for BX211 in Diabetic Foot Osteomyelitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BX211 showed statistically significant ulcer size reduction (PAR) at week 12 (p=0.046) and week 13 (p=0.052) vs placebo.","BX211 reduced ulcer depth (p=0.048) and limited ulcer area expansion (p=0.017) compared to placebo.","Phase 2 trial enrolled 41 patients (26 BX211, 15 placebo) with DFO associated with S. aureus; BX211 safe and well-tolerated.","BiomX plans Phase 2/3 trial pending FDA feedback; KOL event scheduled April 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177203,"accession_number":"0001013762-25-001826","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BiomX reports FY2024 results, $12M financing, Phase 2 DFO readout imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 topline results for BX211 in diabetic foot osteomyelitis expected by end of March 2025.","February 2025 financing raised ~$12M gross proceeds to support BX004 Phase 2b readout in Q1 2026.","Cash and restricted cash $18.0M at Dec 31, 2024; plus $12M raised in Feb 2025; runway into Q1 2026.","FY2024 net loss $17.7M (vs $26.2M); R&D expenses $24.7M; impairments on goodwill, IPR&D, and assets.","Non-dilutive funding from DHA for BX211 totaled $36.8M to date; manufacturing delays for BX004 resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177202,"accession_number":"0001213900-25-020788","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BiomX closes $12M offering; shares outstanding increase to ~25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$12M from registered direct offering, private placement, and warrant exercise.","Offering closed on February 27, 2025.","As of March 5, 2025, outstanding shares of common stock: 24,996,053.","Company trades on NYSE American under ticker PHGE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177201,"accession_number":"0001213900-25-017728","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"BiomX raises $12M in combined offerings; funds BX004 Phase 2b to Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$12M from registered direct offering, private placement, and warrant exercise at $0.9306/share.","Investors include Deerfield Management, Cystic Fibrosis Foundation, and Nantahala Capital.","Proceeds to fund BX004 Phase 2b in CF; topline results expected Q1 2026.","Existing warrants reduced from $2.311 to $0.9306; new warrants issued for 100% of exercised shares.","Also advancing BX211 Phase 2 readout in diabetic foot osteomyelitis this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193977,"accession_number":"0001213900-24-109057","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BiomX regains NYSE American listing compliance after prior deficiencies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from NYSE American on Dec 10, 2024 confirming compliance with continued listing standards.","Resolved prior deficiencies under Sections 1003(a)(i)-(iii) of NYSE American Company Guide raised on May 23, 2024.","Compliance demonstrated for two consecutive quarters per Section 1009(f) of the Company Guide.","No financial or operational updates beyond the compliance notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193976,"accession_number":"0001213900-24-097777","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BiomX Q3 net income $9.6M on warrant revaluation; DFO Phase 2 enrollment complete, CF topline pushed to H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $24.7M as of Sep 30, 2024; company expects runway into Q4 2025.","R&D expenses $7.3M (+30% YoY); G&A $3.2M (+45% YoY); $801K goodwill impairment.","Net income $9.6M vs net loss $7.9M in Q3 2023 due to warrant fair value change.","BX211 DFO Phase 2 patient enrollment done; topline results expected Q1 2025.","BX004 CF Phase 2b topline delayed to H1 2026; manufacturing delays resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193975,"accession_number":"0001213900-24-087459","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BiomX units (PHGE.U) to cease trading on NYSE American Oct 25; warrants expire Oct 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mandatory separation of units into common stock and warrants effective Oct 25, 2024.","Units will no longer trade on NYSE American as of Oct 25; no action required by holders.","Warrants will expire by their terms on Oct 28, 2024.","Common stock continues trading under PHGE on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210305,"accession_number":"0001213900-24-081948","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BiomX provides pipeline update: BX004 Ph2b results in Q3 2025, BX211 Ph2 results in Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BX004 for CF: Phase 2b topline results expected Q3 2025 (60 patients, 2:1 randomized).","BX211 for DFO: Phase 2 topline results expected Q1 2025 (week 26) and Q1 2026 (week 52).","Cash and cash equivalents $32.7M as of June 30, 2024.","Presentation highlights: 14.3% of BX004 patients converted to PsA-negative sputum in Ph1b/2a Part 2.","Peer phage therapy momentum cited: >100 compassionate use cases with 77% clinical improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210304,"accession_number":"0001213900-24-070272","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"BiomX announces 1-for-10 reverse stock split effective August 26, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-10 reverse split on Aug 8, 2024; effective at 12:01 a.m. ET on Aug 26, 2024.","Every 10 existing shares of common stock will convert into 1 share; fractional shares rounded up to whole share.","Units (one share + one warrant) also split-adjusted; new CUSIPs: common 09090D301, units 09090D400.","Outstanding warrants and equity awards adjusted accordingly; trading continues on NYSE American under PHGE and PHGE.U.","No change to authorized share count; stockholders in book-entry or street name need no action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210303,"accession_number":"0001013762-24-001812","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BiomX gets NYSE American approval of compliance plan; deadline extended to Nov 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American accepted BiomX's plan to regain compliance with continued listing standards under Sections 1003(a)(i), (ii), (iii).","Company has until November 23, 2025 to meet listing requirements; stock continues trading on NYSE American under PHGE.","Previously disclosed deficiency in May 2024; plan acceptance avoids immediate delisting but periodic reviews apply.","If compliance not achieved by Nov 2025 or insufficient progress, NYSE American may initiate delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210302,"accession_number":"0001213900-24-060128","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"BiomX shareholders OK 750M authorized shares, reverse split up to 1:10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 120M to 750M, a 6.25x expansion.","Board authorized reverse stock split at ratio 1:5 to 1:10, effective before July 9, 2025.","A&R 2019 LTIP approved with 78M shares initial reserve plus annual 4% evergreen.","Conversion of 256,887 Series X Preferred shares and related warrants into common approved.","Alan Moses and Edward Williams elected as Class I directors until 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228614,"accession_number":"0001213900-24-048030","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"BiomX receives NYSE American delisting notice for equity deficiency; interim CFO departs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' capital deficiency of $9.5M as of March 31, 2024; losses in five recent fiscal years.","Plan to regain compliance due June 22, 2024; final compliance deadline November 23, 2025.","Expects to reclassify $32.4M to equity via Series X Preferred conversion at July 2024 shareholder meeting.","Common stock to trade with '.BC' designation during cure period.","Interim CFO Avraham Gabay steps down May 31, 2024; CFO Marina Wolfson returns from maternity leave."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228611,"accession_number":"0001213900-24-048040","cik":1739174,"company_name":"BiomX Inc.","ticker":"PHGE","form_type":"8-K/A","filed_at":"2024-05-30T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"BiomX files APT financials: net loss $16M, going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APT net loss of $16.0M in 2023 and $23.6M in 2022; accumulated deficit $67.3M at Dec 31, 2023.","APT revenue $14.1M in 2023 vs $5.9M in 2022 from government grants; cash only $1.3M.","Auditor's report includes going concern emphasis; current cash insufficient for 12 months.","APT issued $12.0M of Series B-1 preferred in 2023 but needs additional financing.","Financials filed to complete previously reported acquisition of APT by BiomX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16640285.393548386,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}